IRVINE, Calif., May 30, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that Frank L. Jaksch, Jr., founder and CEO of ChromaDex, will present at the Jefferies 2014 Global Healthcare Conference in New York on Tuesday, June 3, 2014, at 2:00 p.m. EDT.
In addition to his presentation, Mr. Jaksch will be having one-on-one meetings with institutional investors throughout the day. If you would like to schedule a one-on-one meeting, please contact your Jefferies salesperson.
About The Jefferies Global Healthcare Conference:
The conference will feature an extensive range of public & private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare IT and medical technology sectors. This global gathering of leading executives, institutional investors, private equity investors and VCs will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the United States and internationally. The four-day conference will comprise company presentations, Q&A breakout sessions, keynotes and thematic panels. Company management teams and investors will also have the opportunity to participate in one-on-one and small group meetings.
About ChromaDex:
ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G, a natural black rice containing cyanidin-3-glucoside; PURENERGY®, a caffeine-pTeroPure® co-crystal; and NIAGEN, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Contact:
Laura Kelly, Executive Assistant
949-419-0288
laurak@chromadex.com
Quantitative Reconciliation of the differences between the non-GAAP measure and the associated comparable GAAP measure | ||||||||||
Consolidated Statements of Operations | Effects of Non-cash Charges associated with | Consolidated Statements of Operations | ||||||||
(US GAAP) | Share-based Compensation Expense | Excluding Share-based Compensation (Non-GAAP Presentation) | ||||||||
For the Three Months Ended March 29, 2014 and March 30, 2013 | For the Three Months Ended March 29, 2014 and March 30, 2013 | For the Three Months Ended March 29, 2014 and March 30, 2013 | ||||||||
March 29, 2014 | March 30, 2013 | March 29, 2014 | March 30, 2013 | March 29, 2014 | March 30, 2013 | |||||
Sales, net | $ 3,074,138 | $ 2,334,566 | Sales | $ - | $ - | Sales | $ 3,074,138 | $ 2,334,566 | ||
Cost of sales | 2,089,130 | 1,661,726 | Cost of sales | - | - | Cost of sales | 2,089,130 | 1,661,726 | ||
Gross profit | 985,008 | 672,840 | Gross profit | - | - | Gross profit | 985,008 | 672,840 | ||
Operating expenses: | Operating expenses: | Operating expenses: | ||||||||
Sales and marketing | 464,567 | 729,424 | Sales and marketing | - | - | Sales and marketing | 464,567 | 729,424 | ||
General and administrative | 2,337,663 | 1,359,901 | General and administrative | (999,661) | (351,590) | General and administrative | 1,338,002 | 1,008,311 | ||
Loss from investment in affiliate | 21,543 | - | Loss from investment in affiliate | - | - | Loss from investment in affiliate | 21,543 | - | ||
Operating expenses | 2,823,773 | 2,089,325 | Operating expenses | (999,661) | (351,590) | Operating expenses | 1,824,112 | 1,737,735 | ||
Operating loss | (1,838,765) | (1,416,485) | Operating income | 999,661 | 351,590 | Operating loss | (839,104) | (1,064,895) | ||
Nonoperating income (expense): | Nonoperating income: | Nonoperating income (expense): | ||||||||
Interest income | 640 | 204 | Interest income | - | - | Interest income | 640 | 204 | ||
Interest expense | (9,891) | (7,791) | Interest expense | - | - | Interest expense | (9,891) | (7,791) | ||
Nonoperating expense | (9,251) | (7,587) | Nonoperating income | - | - | Nonoperating expense | (9,251) | (7,587) | ||
Net loss | $ (1,848,016) | $ (1,424,072) | Net income | $ 999,661 | $ 351,590 | Net loss | $ (848,355) | $ (1,072,482) | ||
Basic and Diluted loss per common share | $ (0.02) | $ (0.02) | Basic and Diluted income per common share | $ 0.01 | $ 0.00 | Basic and Diluted loss per common share | $ (0.01) | $ (0.01) | ||
Basic and Diluted weighted | Basic and Diluted weighted | Basic and Diluted weighted | ||||||||
average common shares outstanding | 106,076,361 | 94,626,120 | average common shares outstanding | 106,076,361 | 94,626,120 | average common shares outstanding | 106,076,361 | 94,626,120 | ||
SOURCE ChromaDex Corporation
Help employers find you! Check out all the jobs and post your resume.
